Pediatric Hematology

Pediatric hematologists at Cincinnati Children's provide comprehensive specialty care for children and young adults with blood diseases, including those with rare and medically complex conditions. Our physicians and researchers are dedicated to advancing scientific discoveries, developing new treatments, improving disease outcomes, and enhancing the quality of life for patients and their families. As leaders in pediatric hematology our faculty develops, leads, and participates in clinical studies, which means patients have early access to cutting-edge therapies.

CONTACT US

For patient referrals and non-urgent consultation during business hours, contact the program directly at:

Phone: **513-636-4010**

For international inquiries:
Phone: **+1-513-636-3100**
Email: **international@cchmc.org**

www.cincinnatichildrens.org

BEST CHILDREN'S HOSPITALS
U.S.News & WORLD REPORT
HONOR ROLL
2022-23

Cincinnati Children's is ranked #3 in the nation among all Honor Roll hospitals.

COMPREHENSIVE SPECIALTY PROGRAMS

The division's 14 pediatric hematologists offer comprehensive care in the following clinical areas.

- **Hemangioma and Vascular Malformations.** Our center is one of the largest comprehensive vascular anomaly centers in North America, offering multidisciplinary medical, surgical and radiological care. The clinical team follows nearly 4,000 patients and conducts more than 800 new consults each year. We have two nationally recognized Centers of Excellence for Hereditary Hemorrhagic Telangiectasia (HHT) and Sturge-Weber syndrome.
- **Hemoglobinopathies.** Our Comprehensive Sickle Cell Center is a national leader in caring for children with sickle cell disease, thalassemia and other hemoglobin disorders. Our team also provides expert care and diagnostic capabilities for patients with other rare erythrocyte disorders. The Global Hematology team works in Africa and the Caribbean to improve care for children with sickle cell disease living in low-resource countries.
- **Hemostasis and Thrombosis.** Cincinnati Children's provides leading-edge clinical care and diagnostics for children and young adults with bleeding and thrombotic disorders. Special programs in collaboration with other medical specialists include our federally funded Hemophilia Treatment Center, the Young Women's Bleeding Disorder Clinic and participation in the Cerebrovascular Clinic.

MEET THE TEAM

PHYSICIANS

Russell E. Ware, MD, PhD
Director, Division of Hematology

Maria Carter-Febres, MD

Jane Koo, MD

Adrienne Hammill, MD, PhD
Research Director, Hemangioma & Vascular Malformation Program

Theodosia Kalfa, MD, PhD
Co-Director, Erythrocyte Diagnostic Laboratory

Lori Luchtman-Jones, MD
Clinical Director, Hematology Division

Punam Malik, MD
Director, Comprehensive Sickle Cell Center

Eric Mullins, MD
Director, Girls and Women's Bleeding Disorders Clinic

Omar Niss, MD
Director, Hematology Quality Outcomes

Joseph Palumbo, MD
Director, Comprehensive Thrombophilia Center

Charles Quinn, MD, MS
Medical Director, Comprehensive Sickle Cell Center

Kiersten Ricci, MD
Director, Hemangioma & Vascular Malformation Program

Luke Smart, MD
Co-Director, Global Hematology Programs

Cristina Tarango, MD
Director, Hemophilia Treatment Center

OTHER TEAM MEMBERS

Hemangioma & Vascular Malformation Program

Kelly Blache, MSN, CNP-PC

Carol Chute, MSN, APRN, CPNP

Comprehensive Sickle Cell Center, General Hematology

Kelly Clapp, MSN CPNP

Lynette Fenchel, MSN, APRN, FNP

Comprehensive Thrombophilia Center, Hemophilia Treatment Center, General Hematology

Sommer Jones, PA-C

Stephanie Lenahan, PA-C

ADVANCED DIAGNOSTIC AND THERAPEUTIC TESTING

Cincinnati Children's offers highly specialized laboratory testing to assist pediatric and adult hematologists in the diagnosis and care of children with blood diseases. We welcome test requisitions from other institutions and offer clinical consultation and test interpretation, to help healthcare providers deliver the best possible care for their patients..

- The **Erythrocyte Diagnostic Laboratory (EDL)** provides comprehensive, state-of-the-art testing, and interpretation and consultation for disorders involving erythrocytes (Red Blood Cells, RBC). This includes hemoglobin electrophoresis, fetal hemoglobin (HbF) quantitation, globin gene analysis, RBC enzyme analysis, ektacytometry, hemoglobin oximetry, RBC pitted cells, whole blood viscosity, HbF-cell analysis, and genetic modifiers of HbF expression. Collaborative testing with Genetics includes a gene panel that covers 38 genes known to play a role in inherited hemolytic anemias. Dr. Charles Quinn is the medical director and Dr. Theodosia Kalfa is the medical co-director of the EDL.
- The **Hemostasis and Thrombosis Laboratory (HTL)** offers extensive testing for a wide variety of hematological and platelet disorders that affect bleeding and clotting, including many tests that are not widely available. This includes specialized assays such as von Willebrand disease (vWD) panels, vWD multimers, platelet aggregation, and thrombophilia testing. Collaborative testing with Genetics includes a gene panel that covers over 75 genes known to play a role in inherited platelet function disorders. Dr. Lori Luchtman-Jones is the medical director and Dr. Joseph Palumbo is the medical co-director of the HTL.

RESEARCH TO ADVANCE CLINICAL CARE

Research is essential in order to improve the lives and prognosis of patients with blood diseases. Current projects include:

- The Therapeutic Response Evaluation and Adherence Trial (TREAT), which uses pharmacokinetics to determine a sickle cell patient's personalized dose of hydroxyurea in a matter of hours instead of common practice, which may take six to 12 months.
- Over 10 different research studies in sub-Saharan Africa and the Caribbean to promote the diagnosis, surveillance, and treatment of sickle cell disease in low-resource settings.
- A groundbreaking clinical trial testing gene transfer therapy as a disease-modifying therapy and potential cure for sickle cell disease. Early data showed near elimination of chronic pain and sickling events and improved anemia in the first two adult patients.
- Multiple collaborations with the pharmaceutical industry that provide access to groundbreaking hemophilia therapies and thrombosis treatments, including long-acting factor VIII products. We also are participating in two exciting trials for gene therapy for hemophilia A, and multicenter trials of new therapeutics for children with thrombosis.
- The congenital dyserythropoietic anemias (CDA) patient registry, which is the first of its kind in North America. More than 140 patients and family members from 44 institutions have enrolled since the registry began in 2016.
- Multiple opportunities in the Hemangioma and Vascular Malformation Center for patient participation in clinical trials, registries, repositories, questionnaires, and other study initiatives.

082022_BRV163497